Current pharmacological options for the management of primary hyperparathyroidism

Drugs

Volumn 66, Issue 17, 2006, Pages 2189-2211

  Vestergaard, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTIHYPERTENSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITONIN; CIMETIDINE; CINACALCET; CLODRONIC ACID; CONJUGATED ESTROGEN; CORTICOSTEROID; CYCLOFENIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; ETHINYLESTRADIOL; ETIDRONIC ACID; FUROSEMIDE; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE; METHALLENESTRIL; NORETHISTERONE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

ANGINA PECTORIS; ANOREXIA; ARTERIOSCLEROSIS; ASTHENIA; BONE DENSITY; BONE TURNOVER; BREAKTHROUGH BLEEDING; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONVULSION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; EDEMA; ENDOMETRIUM CANCER; ESOPHAGUS DISEASE; ESOPHAGUS EROSION; ESTROGEN THERAPY; FLU LIKE SYNDROME; FLUSHING; FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DEATH; HEART INFARCTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOCALCEMIA; KIDNEY FAILURE; LEG CRAMP; LUNG EMBOLISM; MASTALGIA; META ANALYSIS; MIGRAINE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROLITHIASIS; OSTEOPOROSIS; PAIN; PARATHYROID HORMONE RELEASE; PARESTHESIA; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL; RASH; REHYDRATION; REVIEW; SIDE EFFECT; SKIN IRRITATION; STOMACH ULCER; STROKE; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT INDICATION; ULCERATIVE ESOPHAGITIS; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VOMITING;

BONE DENSITY; CALCIUM; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33845347383     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666170-00004     Document Type: Review

References (103)

1. Jüppner H, Kronenberg HM. Parathyroid hormone. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society for Bone and Mineral Research, 2003: 117-25
2. Joy MS, Kshirsagar AV, Franceschini N. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother 2004; 38: 1871-80
3. Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone 1986; 7: 213-21
4. Charles P, Mosekilde L, Jensen FT. Primary hyperparathyroidism: evaluated by 47calcium kinetics, calcium balance and serum bone-Gla-protein. Eur J Clin Invest 1986; 16: 277-83
5. Rao DS, Wilson RJ, Kleerekoper M, et al. Lack of biomechanical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988; 67: 1294-8
6. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 1995; 80: 729-34
7. Wilson RJ, Rao S, Ellis B, et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988; 109: 959-62
8. Moosgaard B, Vestergaard P, Heickendorff L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005; 63: 506-13
9. Mundy GR, Cove DH, Fisken R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1980; I: 1317-20
10. Bilezikian JP, Potts JT, Fuleihan G, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87: 5353-61
11. Mollerup CL, Vestergaard P, Frøkjær VG, et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 2002; 325: 807-12
12. Smith JC, Page MD, John R, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 3515-9
13. Sancho JJ, Roucho J, Riera-Vidal R, et al. Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg 1992; 16: 732-6
14. Paloyan D, Simonowitz D, Paloyan E, et al. Pancreatitis associated with primary hyperparathyroidism. Am Surg 1982; 48: 366-8
15. Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002; 19: 958-61
16. Vestergaard P, Mollerup CL, Frøkjær VG, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000; 321: 598-602
17. Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism: an update. Eur J Clin Invest 1998; 28: 271-6
18. Hedbäck G, Oden A, Tisell LE. The influence of surgery on the risk of death in patients with primary hyperparathyroidism. World J Surg 1991; 15: 399-405
19. Vestergaard P, Mosekilde L. Cohort study on the effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003; 327: 530-5
20. Eigelberger MS, Cheah WK, Ituarte PH, et al. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg 2004; 239: 528-35
21. Vestergaard P. Anti-resorptive therapy for the prevention of postmenopausal osteoporosis: when should treatment begin? Treat Endocrinol 2005; 4: 263-77
22. Gallagher JC, Nordin BEC. Effects of oestrogen and progestogen therapy on calcium metabolism in post-menopausal women. Front Horm Res 1975; 3: 150-76
23. Gallagher JC, Nordin BEC. Treatment with oestrogens of primary hyperparathyroidism in post-menopausal women. Lancet 1972; I: 503-7
24. Gallagher JC, Wilkinson R. The effect of ethinyloestradiol on calcium and phosphorus metabolism of postmenopausal women with primary hyperparathyroidism. Clin Sci Mol Med 1973; 45: 785-802
25. Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986; 314: 1481-5
26. Marcus R, Madvig P, Crim M, et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984; 100: 633-40
27. Haldimann B, Trechsel U, Dambacher MA, et al. Hyperparathyroidie primaire de la femme agee: effect des oestrogenes sur le metabolism calcique [summary in English]. Schweiz Med Wochenschrift 1982; 112: 1242-5
28. Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomised controlled trial. Ann Intern Med 1996; 125: 360-8
29. Diamond T, Ng AT, Levy S, et al. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporos Int 1996; 6: 329-33
30. Herbai G, Ljunghall S. Treatment of primary hyperparathyroidism with cyclofenil: a synthetic stilbestrol derivative with minimal feminizing effects. Horm Metab Res 1984; 16: 374-6
31. Herbai G, Ljunghall S. Normalization of hypercalcaemia in primary hyperparathyroidism by treatment with methallenestril, a synthetic oestrogen with low oestrogeneicity. Urol Int 1983; 38: 371-3
32. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000; 61: 77-82
33. Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fractures. Contraception 2006; 73: 571-6
34. Cooper C, Hannaford P, Croft P, et al. Oral contraceptive pill use and fractures in women: a prospective study. Bone 1993; 14: 41-5
35. Michaelsson K, Baron JA, Farahmand BY, et al. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 1999; 353: 1481-4
36. Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture: findings in a large cohort study. Contraception 1998; 57: 231-5
37. Goldfien A. The gonadal hormones & inhibitors. In: Katzung BG, editor. Basic and clinical pharmacology. East Norwalk (CT): Appleton & Lange, 1987: 461-83
38. McDermott MT, Perloff JJ, Kidd GS. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Mineral Res 1994; 9: 509-14
39. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
40. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-38
41. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12
42. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891-7
43. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001; 2: 7-10
44. Vestergaard P, Rejnmark L, Mosekilde L. Fracture reducing potential of hormone replacement therapy on a population level. Maturitas 2006; 54: 285-93
45. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-4
46. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37
47. Horowitz M, Wishart J, Need AG, et al. Treatment of postmenopausal hyperparathyroidism with norethindrone. Arch Intern Med 1987; 147: 681-5
48. Zanchetta JR, Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 2001; 16: 189-90
49. Rubin MR, Lee KH, McMahon DJ, et al. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 1174-8
50. Stone MD, Marshall DH, Hosking DJ, et al. Comparison of low-dose intramuscular and intravenous salcatonin in the treatment of primary hyperparathyroidism. Bone 1992; 13: 265-71
51. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-17
52. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45
53. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-61
54. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-57
55. Torring O, Bucht E, Sjostedt U, et al. Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism. Bone 1991; 12: 311-6
56. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 540-51
57. Chesnut CH, Silverman S, Andriano KA, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109: 267-76
58. Rossini M, Gatti D, Isaia G, et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Mineral Res 2001; 16: 113-9
59. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 3319-25
60. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 581-7
61. Parker CR, Blackwell PJ, Fairbairn KJ, et al. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 2002; 87: 4482-9
62. LoCascio V, Braga V, Bertoldo F, et al. Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994; 41: 47-51
63. Adami S, Zamberlan N, Mian M, et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Miner 1994; 25: 75-82
64. Horiuchi T, Onouchi T, Inoue J, et al. A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. Gerontology 2002; 48: 103-8
65. Hamdy NA, Gray RE, McCloskey E, et al. Clodronate in the medical management of hyperparathyroidism. Bone 1987; 8: S69-77
66. Shane E, Baquiran DC, Bilezikian JP. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 1981; 95: 23-7
67. Douglas DL, Kanis JA, Paterson AD, et al. Drug treatment of primary hyperparathyroidism: use of clodronate disodium. BMJ (Clin Res Ed) 1983; 286: 587-90
68. Ammann P, Herter-Clavel C, Lubrano A, et al. A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism. Aging Clin Exp Res 2003; 15: 500-4
69. Reasner CA, Stone MD, Hosking DJ, et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993; 77: 1067-71
70. Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508-16
71. Black DM, Cummings SR, Kerpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41
72. Douglas DL, Duckworth T, Russell RG, et al. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1980; 1: 1043-7
73. Hoffmeyer P, Groebli Y, Spiliopoulos A, et al. Clodronate therapy of hypercalcemia caused by hyperparathyroidism [in German]. Schweiz Med Wochenschr 1982; 112: 118-20
74. McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004; 19: 728-36
75. Licata AA, O'Hanlon E. Treatment of hyperparathyroidism with etidronate sodium. JAMA 1983; 249: 2063-4
76. Kaplan RA, Geho WB, Poindexter C, et al. Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol 1977; 37: 410-9
77. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Int 2001; 12: 140-51
78. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517-23
79. Häuselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis Int 2003; 14: 2-12
80. Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057-64
81. Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 1595-9
82. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-21
83. Quarles LD. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens 2003; 12: 349-55
84. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 135-41
85. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 5644-9
86. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-25
87. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-54
88. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-83
89. Rubin M, Sliney J, McCary LC, et al. Effective management of severe hypercalcemia with the calcimimetic cinacalcet HCI in patients with parathyroid carcinoma. J Bone Miner Res 2003; 18 Suppl. 2: S392
90. Rubin MR, Sliney J, Silverberg SJ, et al. Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCl. J Bone Miner Res 2004; 19 Suppl. 1: S103
91. Silverberg SJ, Faiman C, Bilezikian JP, et al. Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma. J Bone Miner Res 2004; 19 Suppl. 1: S103
92. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-24
93. Hasling C, Charles P, Mosekilde L. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study. Euro J Clin Invest 1986; 16: 433-7
94. Pecherstorfer M, Brenner K, Zojer N. Current management strategies for hypercalcemia. Treat Endocrinol 2003; 2: 273-92
95. Wisneski LA, Croom WP, Silva OL, et al. Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 1978; 24: 219-22
96. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; 2: 1180-2
97. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996; 14: 158-70
98. Kantorovich V, Gacad MA, Seeger LL, et al. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 3541-3
99. Lind L, Wengle B, Sorensen OH, et al. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism. Acta Endocrinol (Copenh) 1989; 120: 250-6
100. Broadus AE, Magee JS, Mallette LE, et al. A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism. J Clin Endocrinol Metab 1983; 56: 953-61
101. Ljunghall S, Rudberg C, Åkerström G, et al. Effects of beta-adrenergic blockade on serum parathyroid hormone in normal subjects and patients with primary hyperparathyroidism. Acta Med Scand 1982; 211: 27-30
102. Fisken RA, Wilkinson R, Heath DA. The effects of cimetidine on serum calcium and parathyroid hormone levels in primary hyperparathyroidism. Br J Clin Pharmacol 1982; 14: 701-5
103. Wiske PS, Epstein S, Norton JA, et al. The effects of intravenous and oral cimetidine in primary hyperparathyroidism. Horm Metab Res 1983; 15: 245-8